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Arginine deiminase (ADI), an arginine-metabolizing enzyme involved in cell signaling, is dysregulated in multiple inflammatory
diseases and cancers. We hypothesized that pegylated ADI (ADI-PEG) provide protection against colitis. Methods. Dextran sodium
sulfate colitis was induced in IL-10-deficient and BALB/c (WT) mice. ADI-PEG was administered i.p., and inflammatory mediators
and pathology were evaluated. Results. Acute colitis in mice was manifested by increases in inflammatory biomarkers, such as
serum amyloid A (SAA, P < 0.001), IL-12 p40, and disease index (3-Fold). In contrast, ADI-PEG significantly decreased clinical
disease index, SAA levels, and inflammatory cytokines in blood as well as in colonic explants. Animals developed moderate (2.2 ±
0.3 WT) to severe (3.6 ± 0.5 IL-10 deficient) colonic pathology; and ADI-PEG treatment significantly improved the severity of
colitis (P < 0.05). Marked infiltration of CD68+ macrophages and iNOS expression were detected in colonic submucosa in colitic
animals but not detected in ADI-PEG-treated animals. Conclusion. ADI-PEG attenuated inflammatory responses by suppression
of macrophage infiltration and iNOS expression in colitic animals. ADI-PEG can serve as a potential therapeutic value in IBD.

1. Introduction
Arginine deiminase (ADI) plays important role in cell signaling pathways, including apoptosis, diﬀerentiation, and transcriptional regulation [1, 2]. ADI is an arginine-degrading
enzyme that catalyzes the hydrolysis of peptidylarginine to
form peptidylcitrulline. ADI activity is dysregulated in multiple human diseases including rheumatoid arthritis (RA),
inflammatory bowel disease (IBD), and cancer. Since, tumor
cell lines require arginine for growth, selective elimination
of arginine from the circulation has been suggested as a
potential cancer treatment modality and currently in use in
human trials [3]. Conversely, ADI inhibition with cl-amidine
has been shown to reduce disease severity in the collageninduced arthritis model of RA [4, 5].
Nitric oxide (NO) is known to be elevated in the colonic
tissues of patients with active IBD and increased NO production and nitric oxide synthase (NOS) activity are detected
in cultured mucosal explants from patients with active IBD,

both ulcerative colitis and Crohn’s disease [6–9]. Immunohistochemical analysis has identified inducible nitric oxide
synthase (iNOS), a key inflammatory mediator, responsible
for generation of NO and as the NOS isoform elevated
in IBD [10, 11]. This increase-associated iNOS is localized
to macrophages and epithelial cells, particularly in luminal
epithelia that expose colonic tissue [11].
Additionally, the expression of iNOS in circulating
monocytes and the percentage of iNOS-positive monocytes
are increased in patients with active IBD as compared to
healthy controls [12]. Arginine metabolism is likely to be
another factor with regard to the roles of NOS in colitis. In
addition to serving as a NOS substrate, arginine is a mediator
for the enzyme arginase, which synthesizes ornithine, an
intermediate in polyamine biosynthesis. Polyamines have
been suggested to protect against colitis, possibly by stimulating reepithelialization and increasing arginase activity
associated with healing following experimental colonic anastomosis [13, 14]. Arginine, is a nonessential amino acid,
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synthesized in normal cells and tissues from citrulline in a
2-step process using the urea cycle enzymes argininosuccinate synthase and argininosuccinate lyase. As an arginine
metabolizing enzyme, ADI (Scheme 1), has major properties
with respect to the issues of harmful and helpful NO and
alternative arginine metabolism with preventing harmful
NO generation [15].
In fact, the native ADI is very immunogenic with a
short circulating lifespan of only 5 h. ADI covalently binds to
polyethylene glycol (PEG) with molecular weight of 20 kDa
and forms ADI-PEG. ADI-PEG is less antigenic with a
significant increased circulating life span of about 5 days and
reported to be safe in mice as well as humans [3, 16].
Although, ADI plays an important role in regulating cell
signaling, the mechanism by which the enzyme’s activity
is regulated under physiological as well as pathological
conditions leading to IBD is not fully discovered. Here we
hypothesized the potential protective action of a microbial
enzyme, ADI-PEG treatment against acute colitis.

2. Methods
Pegylated arginine deiminase (ADI-PEG) was prepared and
provided by Dr. Steiner (University of KY; USA). Briefly,
nonmammalian ADI gene from Mycoplasma hominis was
expressed in E. coli and purified by anion-exchange chromatography with a POROS HQ resin column. The recombinant ADI was then pegylated according to the manufacture
recommendation, and the enzyme activity was measured
[16].
2.1. Animals. This study was approved and performed in
accordance with the guidelines for the care and use of laboratory animals at the accredited University of Kentucky and
Veterans Administration (VA) Medical Center in Lexington,
KY, USA. IL-10-deficient mice were bred in animal facility at
VA Medical Center and UK Medical Center. Male pups were
weaned and at 5 weeks of age enrolled in this study.
In addition, five-week-old male BALB/c wildtype mice
were purchased from Harlan Laboratories (Indianapolis, IN)
and acclimatized for 10 days prior to the experiment. The IL10-deficient mice were cohoused with wildtype mice (WT)
in conventional condition, in microisolator cages, with free
access to water and food (Harlan Teklad Laboratory Diet,
Madison, WI) and kept in a room with a 12 h light/dark cycle.
2.2. Colitis Induction. Colitis was induced in IL-10-deficientand WT mice by oral ingestion of 3% dextran sodium sulfate
(DSS) for 7 days and assessed by clinical disease index,
inflammatory mediators, and histological grading scores.
ADI-PEG low dose (5 IU) and high dose (10 IU) were chosen
based on the safe and eﬀective doses detected in previous cell
culture studies. ADI-PEG was administered i.p. on day 0 and
day 5 to the treated groups as ADI-PEG has a 1/2 lifespan of
about 5-6 days.
2.3. The Clinical Disease Index. The clinical disease activity
score was determined by the mean measurement of animal
survival, extent of weight loss, stool consistency, presence of
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Scheme 1: Arginine metabolism.

blood in the stool, anemia as expressed by the hematocrit,
colonic weight and length, and prolapse collectively which
were scored from 0, to present normal up to 10, the most
severe case.
2.4. Colonic Histopathology. Colonic tissues were flushed
with ice-cold phosphate-buﬀered saline (PBS pH 7.2) and
cut longitudinally in half. One portion of each colon was
Swiss-rolled and fixed in 10% formalin for histological examination. The remainder was snap-frozen in liquid nitrogen
and stored at −80◦ C. The formalin fixed sections were
processed and stained with hematoxylin and eosin (H and E)
and evaluated under light microscopy. Severity of colitis was
assessed with a histological semiquantitative grading score
[17] and in a blinded manner. The scores were based on
histological features with a numeric value (0 to 4) assigned
according to the tissue involvement and severity of lesions
that corresponded to either of the following criteria:
grade (0): No detectable lesions, no inflammatory
cells, and normal mucosal appearance,
grade (1): Focal inflammatory infiltrate in the mucosa (25% involved),
grade (2): Mild multi-focal inflammation with moderate expansion to the mucosa (50% involved),
grade (3): Moderate multifocal inflammation with
moderate expansion of the mucosa (75% involved),
grade (4): Severe diﬀuse inflammation with crypt
epithelium disruption and ulceration (over 75%
involved).
2.5. Plasma Analysis for Inflammatory Biomarkers Concentrations. Blood was collected via right heart ventricle puncture
in lightly heparinized syringes and kept on ice. Sera were
separated by 5 min centrifugation at 5000 ×g and stored at
−80◦ C prior to the analysis.
2.6. Colonic Explant Production of Cytokines. Proximal sections of cleansed colonic cuﬀs from each mouse were
weighted and washed with sterile PBS and the RPMI 1640
culture medium. Each explant was then plated in 24-well
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2.7. Inflammatory Biomarkers. Cytokines were measured by
ELISA kits and assayed according to the manufacture’s
recommendation. The concentrations of IL-6, IL-12p40, and
TNFα were measured by ELISA kits obtained from R and
D (Minneapolis, MN, USA), and SAA was analyzed by Kits
from BioSource (Camarillo, CA, USA).
2.8. Immunohistochemical Assay (IHC). Paraﬃn-embedded
sections were cut, deparaﬃnized with hexane, rehydrated
in alcohol baths, washed in PBS, microwaved in antigen
retrieval solution (high pH; DAKO, Carpenteria, CA, USA)
for 5 min, washed with PBS, incubated in 0.3% H2 O2 methanol for 10 min, and then rinsed with water. Slides
were incubated at room temperature for 1.5 h in a blocking
solution consisting of normal serum, rinsed with PBS, and
then incubated with primary antibody at 4◦ C overnight.
Rabbit polyclonal IgG against CD68 and iNOS was obtained
from Zymed-Invitrogen. Invitrogen (Carlsbad, CA, USA)
and Millipore (Billerica, MA, USA) respectively. The “Elite
ABC” kit was used with biotinylated secondary antibodies
and biotin-conjugated horseradish peroxidase and then
developed using a 3-3 -diaminobenzidine solution per
manufacturer’s instructions. The slides were subsequently
counterstained with Methyl Green (Dako, Carpenteria, CA,
USA). The CD68 (the macrophage specific-marker) staining
for the quantification of macrophages and anti-iNOS (iNOS
positive macrophage) for the assessment of iNOS expression
was performed to evaluate macrophage infiltration and
activation in colonic tissue [18].
2.9. Nitric Oxide (NO) Analysis. NO was assessed indirectly
by the measurement of its breakdown products, nitrite plus
nitrate [19], in a microtiter plate assay. Briefly, nitrate was
reduced into nitrite by incubation with nitrate reductase,
untreated NADPH was oxidized, and then total nitrite was
colorimetrically measured following incubation with the
Griess reagent. Griess reagent: 1% (w/v) ammonium chloride
was adjusted to pH 8.0 with sodium borate, 1 : 1solution of
0.1% (w/v) N-(1-naphthyl) ethylenediamine dihydrochloride, and 1% (w/v) sulfanilamide, in 5% (v/v) phosphoric
acid.
2.10. Statistical Analysis. Results are expressed as the mean ±
SEM unless otherwise stated. Data was analyzed with
ANOVA followed by appropriate post hoc test (Tukey compared all pairs) using GraphPad Instat version 3 for Windows
(San Diego, CA, USA). Statistical significance was set at P <
0.05.
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P < 0.05

P < 0.05
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Clinical disease score

plates and cultured in 1 mL of complete RPMI 1640
medium supplemented with 5% fetal bovine serum (FBS,
BioWhittaker, Walkersville, MD, USA) for 24 h at 37◦ C. LPS
(10 ng/mL) was added into duplicate wells to stimulate the
cells. Culture supernatant was collected with centrifugation,
and aliquots were stored at −80◦ C until analyzed for
inflammatory markers.
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Figure 1: Eﬀects of ADI-PEG therapy on the clinical disease index
in DSS-induced acute colitis. ADI-PEG was administered i.p on day
0 and day 5. Clinical disease index was determined by parameters
as means for extent of weight loss, presence of diarrhea, rectal
bleeding, prolapse, and anemia (n = 6/group). ADI-PEG markedly
decreased the clinical disease index in WT and IL-10-deficient
colitic mice.

3. Results
Colitis was induced in WT and IL-10-deficient mice by oral
ingestion of DSS in daily drinking water for 7 days. ADI-PEG
was administered i.p. on day 0 and day 5 to the treated groups
(ADI-PEG circulating 1/2 life is 5 days). Clinical disease
index was determined by using parameters such as survival,
extent of weight loss, the presence or absence of diarrhea,
rectal bleeding, anemia, and prolapse.
DSS-exposed IL-10-deficient and WT animals all lost
weight and developed anemia due to blood loss. In contrast,
ADI-PEG treatment significantly protected DSS-exposed
mice from weight loss and rectal bleeding compared to
untreated DSS colitic animals (data shown collectively as
disease index Figure 1). Over 80% of animals in both
IL-10-deficient and WT groups developed diarrhea and
occult blood, whereas only IL-10-deficient colitic animals
progressed to prolapse. In contrast, ADI-PEG treatment
significantly protected WT as well as IL-10-deficient animals
against diarrhea, occult blood, and prolapse (Figure 1).
Colitic animals developed significant increases at the levels
of inflammatory cytokines including plasma concentrations
of IL-6 and IL-12p40 (Tables 1 and 2). Additionally, marked
increases in the production of TNFα (Figure 2), IL-6, and
IL-12p40 were noted in the stimulated colonic explants
(Tables 1 and 2) corresponding to inflammatory response
in colitic mice both IL-10 deficient and WTs. In contrast,
ADI-PEG-treated animals had a significant reduction of
these inflammatory cytokines (P < 0.05) in their stimulated
colonic explants (Tables 1 and 2).
Acute inflammatory biomarker, serum amyloid A (SAA),
was significantly increased in the colitic IL-10-deficient (400fold) and WT (30-fold) animals, while, ADI-PEG-treated
animals exhibited significant reduction at the levels of SAA
biomarker compared to untreated colitic animals (Tables 1
and 2). In addition, there was a significant increase at the
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Table 1: IL-10 deficient-mice: comparison of inflammatory markers in plasma and colonic explants in IL-10-deficient (IL-10−/−) mice
treated with DSS and ADI-PEG versus sham controls. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.
Inflammatory markers
IL-6 (pg/mL)
Control
24 ± 3
ADI
25 ± 4
DSS
202 ± 28∗∗
DSS + ADI-PEG (low dose)
49 ± 15
DSS + ADI-PEG (high dose)
126 ± 20∗

Plasma
IL-12p40 (pg/mL)
233 ± 18
297 ± 13
319 ± 20
292 ± 23
295 ± 7

SAA (μg/mL)
3±1
38 ± 31
1591 ± 550∗∗∗
276 ± 130∗∗
1105 ± 662∗

NO (μM)
80 ± 5
50 ± 5
205 ± 39∗
60 ± 2
90 ± 20

Colonic explant + LPS
IL-6 (ng/mL)
IL-12p40 (pg/mL)
126 ± 54
170 ± 56
179 ± 83
199 ± 113
1768 ± 629∗∗∗
1194 + 130∗∗
∗
257 ± 73
255 ± 28∗
108 ± 41∗∗
313 ± 85

Table 2: WT mice: comparison of inflammatory markers in plasma and colonic explants in BALB/c (WT) mice treated with DSS and
ADI-PEG versus sham controls. ∗ P < 0.05, ∗∗ P < 0.01, and ∗∗∗ P < 0.001.
Inflammatory markers
Control
ADI
DSS
DSS + ADI-PEG (Low dose)

IL-6 (pg/mL)
45 ± 14
27 ± 5
182 ± 27∗
55 ± 9

1000

Plasma
SAA (μg/mL)
12 ± 1
48 ± 37
427 + 121∗∗
24 + 12∗

NO (μM)
24 ± 1
27 ± 2.5
36 ± 3
24 ± 3

Colonic explant + LPS
IL-12p40 (pg/mL)
550 ± 25
650 ± 50
875 ± 150∗
475 ± 50

P < 0.05

P < 0.05
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Figure 2: ADI-PEG treatment significantly decreased inflammatory
response to LPS-stimulated TNFα production by colonic explants
(P < 0.05).

plasma levels of NO production presumably released mainly
from activated macrophages/monocytes. NO production was
measured as the concentration of NO breakdown products
(nitrate + nitrite) and was increased 2-fold in the colitic
IL-10-deficient animals as compared to normal controls.
Contrary to IL-10-deficient animals, the excess NO release
did not reach statistical significance in WT animals as colitis
was less severe in WT mice compared to IL-10-deficient
counterparts. ADI-PEG treatment significantly ameliorated
the NO release in colitic animals (Tables 1 and 2).
3.1. Colonic Histopathology. DSS administration induced
moderate colitis (2.2 ± 0.3) in WT mice to severe cases
(3.6 ± 0.5) in IL-10-deficient mice (Figure 3) possibly due to
more severe immune reaction to overgrowth of gut microbial
due to the lack of protective IL-10 and overactivation of
macrophages and inflammatory cells. This was in accordance

0
DSS

ADI + DSS
IL-10 −/−

DSS

ADI + DSS
WT

Figure 3: Eﬀect of ADI-PEG on histopathology scores (0–
4) according to the severity of lesions in DSS-colitic animals.
Histopathological assessment revealed that ADI-PEG markedly
attenuated DSS-induced colitis in WT as well as IL-10 deficient
mice. (n = 6/group).

with pathological manifestations including shortening of
crypts, loss of brush boarder epithelial cells, thickening
of submucosa, and ulcer formation in colitic animals as
confirmed in histological sections (Figure 3). In general,
the H and E histological damage scores were consistent
with infiltration of inflammatory cells, extensive macrophage
proliferation, followed by shortening of colonic length, and
increased disease index in the colitic WT as well as IL-10deficient animals. Furthermore, marked CD68+ macrophage
infiltration in the submucosa of the colonic tissue was
confirmed by immunohistochemical analysis in WT and
IL-10-deficient colitic animals. Similar to CD68+ specific
macrophage infiltration, the expression of macrophage
derived iNOS was upregulated in the colonic macrophages
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Figure 4: Eﬀect of ADI-PEG on macrophage infiltration in colonic tissue from colitic IL-10-deficient mice. ADI-PEG markedly decreased
submucosal macrophage infiltration and iNOS expression in DSS-induced colitic IL-10-deficient as well as WT mice (not shown). (n =
6/group).

(Figure 4) as well as local gut epithelia, supporting the
notion that ADI-PEG provides protection against colitis
by preventing CD68+ macrophage proliferation and iNOS
activation in colonic tissues from IL-10 deficient and to a
lesser extent in WT animals (data not shown).
Therefore, ADI-PEG-treated animals developed significantly less severe colitis as manifested by improved disease
index (survival and increased body weight), decreased
levels of inflammatory biomarkers, and decreased distal
and proximal colonic histological damage scores. Colonic
explants from ADI-PEG-treated mice released significantly
less inflammatory cytokines compared with untreated DSScolitic mice. Collectively, ADI-PEG was better tolerated in
low dose and was more eﬀective in normalizing SAA, plasma
IL-6, and NO compared to high dose against colitis in
animals (Table 1).

4. Discussion
These data demonstrate that ADI formulated with polyethylene glycol (ADI-PEG) eﬀectively attenuated colonic inflammatory response induced in 2 phenotypic distinct IBD
murine models. As anticipated in DSS-induced colitis model,
the levels of the acute phase protein, SAA, are significantly
elevated due to inflammatory cascade as occurs in colitic
animals [17, 18, 20]. ADI-PEG markedly ameliorated the
elevated levels of inflammatory mediators including SAA,

IL-6, and IL-12p40, in sera as well as in colonic explants’
supernatants from treated animals. IL-12p40 is specifically
released by the activated macrophages involved in Th-1
mediated immune responses.
Macrophage infiltration and activation are one of the
major potential mechanisms of DSS-induced colitis in
animals presumably due to the overgrowth of gram-negative
bacteria and are regulated by the luminal microbiota [21]. As
CD68+ -macrophage-specific marker and the iNOS activity
in the colonic tissues were significantly elevated following
inflammatory cascades by infiltration and activation of
macrophages in both WT as well as IL-10-deficient colitic
animals. Our data indicate that pegylated ADI eﬀectively
attenuates intestinal inflammation induced in colitis and
diminishes macrophage proliferation and activation in these
colitic animals.
The luminal NO level is shown to be increased in IBD
patients [7, 8], and the plasma NO is elevated in active
ulcerative colitis and Crohn’s disease versus inactive state or
normal controls [9]. Additionally, gene expression (mRNA)
of inducible nitric oxide synthase, iNOS, is elevated in
Crohn’s and ulcerative colitis patients [22]. In addition, 2fold increases at the plasma levels of NO production were
presumably released from activated macrophages/monocytes
in the colitic IL-10-deficient animals as compared to the
normal controls. In contrast, the excess NO release did not
reach statistical significance in WT animals, as colitis was less
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severe in WT mice compared to IL-10-deficient counterparts.
In this study, the reduction in the colonic inflammation
is possibly associated with decreased macrophage-derived
NO release by ADI-PEG, as demonstrated by a significant
decrease in macrophage infiltration and iNOS expression in
WTs as well as IL-10 deficient mice. Further, nNOS appears
to protect against DSS-induced colitis, since disease is more
severe in nNOS−/− mice as compared to WT animals [23].
These findings indicate that ADI-PEG is a promising agent
for the elucidation of the role of arginine-related events in
the pathogenesis of colitis.
However, there is controversy with regard to the role of
NO in IBD since NO has been shown to have some protective
role, indicating reduction in double IL-10/iNOS−/− mice
[24] and some beneficial eﬀect with an NO donor [25].
Dissimilarity in experimental design may contribute to some
of these variations [26]. Also, that NO may play dual
function, both deleterious and protective function in the
gut [27]. It is anticipated that inflammation-related NO
synthesized by macrophage iNOS is highly pathogenic, while
intestinal epithelial iNOS may synthesize protective NO in
nature and function in healing and reepithelialization [28,
29]. In addition, increased arginase activity is observed in
IBD [30]. Arginine metabolism is likely to be another factor
with regard to the roles of NOS in colitis. Macrophage
arginase expression is stimulated by lipopolysaccharides,
LPS, IL-10, alone or in combination to (LPS + IL-10), a
protective cytokine in IBD, which synergizes with respect
to increased arginine expression [31]. Indeed, as proposed previously “more global” considerations of arginine
metabolism, particularly arginase and NOS, might be the key
elements to reveal the roles of NO in IBD [32] and further
the potential mechanism of ADI-PEG on the development of
IBD.
In the current study, the microbial enzyme, Mycoplasma
hominis ADI gene was cloned and expressed in Escherichia
coli and then conjugated with PEG to increase the circulating
half-life from 5 h to 5 days and to drastically decrease the
immunogenicity of the recombinant enzyme [16]. Generally,
ADI converts plasma arginine into citrulline, a metabolite
which is taken up and converted back into arginine only
by normal cells and tissues but not by tumor cells such
as hepatocellular carcinoma [33]. The reduction in the
intestinal inflammation is related to decreased inflammatory
cytokines as well as decreased macrophage-derived NO levels
by ADI-PEG, as shown by reduced macrophage infiltration
and colonic iNOS expression.
Overall, DSS-induced colitis was more severe in IL-10
deficient mice than in WT animals as IL-10 cytokine plays
an important role as an anti-inflammatory element with a
protective action against colitis [20]. Also, that ADI-PEG
acts through the inhibition of macrophage activation and
proliferation.
Overall, ADI-PEG significantly ameliorated colitic symptoms and pathology in treated animals by blocking infiltration/proliferation of these inflammatory cells in tissues.
Therefore, ADI-PEG is a possible promising agent against
colitis as well as for the elucidation of the role of argininerelated events in the pathogenesis of colitis.
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5. Conclusion
ADI-PEG treatment protects against colitis in 2 distinct phenotypic animal models, BALB/c wildtypes as well as IL-10
deficient mice, presumably due to the attenuation of inflammatory markers such as SAA, suppression of macrophage
infiltration, and iNOS expression in colonic tissues. As
such, ADI-PEG can serve as a potential therapeutic value in
IBD.
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